1
|
Lin HB, Naito K, Oh Y, Farber G, Kanaan G, Valaperti A, Dawood F, Zhang L, Li GH, Smyth D, Moon M, Liu Y, Liang W, Rotstein B, Philpott DJ, Kim KH, Harper ME, Liu PP. Innate Immune Nod1/RIP2 Signaling Is Essential for Cardiac Hypertrophy but Requires Mitochondrial Antiviral Signaling Protein for Signal Transductions and Energy Balance. Circulation 2020; 142:2240-2258. [PMID: 33070627 DOI: 10.1161/circulationaha.119.041213] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND Cardiac hypertrophy is a key biological response to injurious stresses such as pressure overload and, when excessive, can lead to heart failure. Innate immune activation by danger signals, through intracellular pattern recognition receptors such as nucleotide-binding oligomerization domain 1 (Nod1) and its adaptor receptor-interacting protein 2 (RIP2), might play a major role in cardiac remodeling and progression to heart failure. We hypothesize that Nod1/RIP2 are major contributors to cardiac hypertrophy, but may not be sufficient to fully express the phenotype alone. METHODS To elucidate the contribution of Nod1/RIP2 signaling to cardiac hypertrophy, we randomized Nod1-/-, RIP2-/-, or wild-type mice to transverse aortic constriction or sham operations. Cardiac hypertrophy, fibrosis, and cardiac function were examined in these mice. RESULTS Nod1 and RIP2 proteins were upregulated in the heart after transverse aortic constriction, and this was paralleled by increased expression of mitochondrial proteins, including mitochondrial antiviral signaling protein (MAVS). Nod1-/- and RIP2-/- mice subjected to transverse aortic constriction exhibited better survival, improved cardiac function, and decreased cardiac hypertrophy. Downstream signal transduction pathways that regulate inflammation and fibrosis, including NF (nuclear factor) κB and MAPK (mitogen-activated protein kinase)-GATA4/p300, were reduced in both Nod1-/- and RIP2-/- mice after transverse aortic constriction compared with wild-type mice. Coimmunoprecipitation of extracted cardiac proteins and confocal immunofluorescence microscopy showed that Nod1/RIP2 interaction was robust and that this complex also included MAVS as an essential component. Suppression of MAVS expression attenuated the complex formation, NF κB signaling, and myocyte hypertrophy. Interrogation of mitochondrial function compared in the presence or ablation of MAVS revealed that MAVS serves to suppress mitochondrial energy output and mediate fission/fusion related dynamic changes. The latter is possibly linked to mitophagy during cardiomyocytes stress, which may provide an intriguing link between innate immune activation and mitochondrial energy balance under stress or injury conditions. CONCLUSIONS We have identified that innate immune Nod1/RIP2 signaling is a major contributor to cardiac remodeling after stress. This process is critically joined by and regulated through the mitochondrial danger signal adapter MAVS. This novel complex coordinates remodeling, inflammatory response, and mitochondrial energy metabolism in stressed cardiomyocytes. Thus, Nod1/RIP2/MAVS signaling complex may represent an attractive new therapeutic approach toward heart failure.
Collapse
Affiliation(s)
- Han-Bin Lin
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Kotaro Naito
- Cardiology, Keiyu Hospital, Yokohama, Japan (K.N.).,University Health Network (K.N., A.V., F.D., M.M., Y.L., P.P.L.), University of Toronto, Canada
| | - Yena Oh
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Gedaliah Farber
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Georges Kanaan
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine (G.K., B.R., M.-E.H.), University of Ottawa, Canada
| | - Alan Valaperti
- Department of Clinical Immunology of the University Hospital Zurich, Switzerland (A.V.).,University Health Network (K.N., A.V., F.D., M.M., Y.L., P.P.L.), University of Toronto, Canada
| | - Fayez Dawood
- University Health Network (K.N., A.V., F.D., M.M., Y.L., P.P.L.), University of Toronto, Canada
| | - Liyong Zhang
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Guo Hua Li
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - David Smyth
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Mark Moon
- Department of Physiology, Institute of Medical Science (M.M., P.P.L.), University of Toronto, Canada.,University Health Network (K.N., A.V., F.D., M.M., Y.L., P.P.L.), University of Toronto, Canada
| | - Youan Liu
- University Health Network (K.N., A.V., F.D., M.M., Y.L., P.P.L.), University of Toronto, Canada
| | - Wenbin Liang
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Benjamin Rotstein
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine (G.K., B.R., M.-E.H.), University of Ottawa, Canada
| | | | - Kyoung-Han Kim
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada
| | - Mary-Ellen Harper
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine (G.K., B.R., M.-E.H.), University of Ottawa, Canada
| | - Peter P Liu
- University of Ottawa Heart Institute (H.-B.L., Y.O., G.F., L.Z., G.H.L., D.S., W.L., B.R., K.-H.K., P.P.L.), University of Ottawa, Canada.,Departments of Medicine and Cellular and Molecular Medicine (H.-B.L., Y.O., L.Z., G.H.L., D.S., W.L., K.-H.K., P.P.L.), University of Ottawa, Canada.,Department of Physiology, Institute of Medical Science (M.M., P.P.L.), University of Toronto, Canada.,University Health Network (K.N., A.V., F.D., M.M., Y.L., P.P.L.), University of Toronto, Canada
| |
Collapse
|
2
|
Ohashi R, Fukazawa R, Watanabe M, Hashimoto K, Suzuki N, Nagi-Miura N, Ohno N, Shimizu A, Itoh Y. Characterization of a murine model with arteritis induced by Nod1 ligand, FK565: A comparative study with a CAWS-induced model. Mod Rheumatol 2017; 27:1024-1030. [PMID: 28150515 DOI: 10.1080/14397595.2017.1287150] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVE Kawasaki disease (KD) occurs via activation of the innate immune system. Nucleotide oligomerization domain-1 (NOD1) is a pattern recognition receptor regulating the innate immunity. We characterized histopathology of arteritis induced by FK565, a ligand for NOD1, in mice, compared with Candida albicans water-soluble fraction (CAWS)-induced model. METHODS Vasculitis was induced by injection of FK565 or CAWS into C57BL6/J mice (n = 9 and n = 11, respectively). At 4 weeks, they were sacrificed, and plasma cytokines and chemokines were measured. RESULTS FK565 injection induced vasculitis mainly involving bilateral coronary arteries whereas the aortic root was diffusely affected in CAWS mice. In FK565 animals, the abdominal aorta and its branching arteries also exhibited inflammation with atherosclerosis. IL-1α, IL-1β, IL-5 and RANTES were increased in FK565 group whereas IL-6, IL-13, G-CSF, IFN-γ, and TNF-α were higher in CAWS animals (p < .05 for all variables). The total area of inflammation in FK565 mice appeared to correlate with IL-1β levels (r = 0.71, p = .05). CONCLUSIONS Histopathology of FK565-induced model demonstrated 'site-specific' coronary arteritis mimicking KD. This histopathological difference from CAWS model may be due to different cytokine expression profiles.
Collapse
Affiliation(s)
- Ryuji Ohashi
- a Department of Diagnostic Pathology , Nippon Medical School Hospital , Tokyo , Japan
| | - Ryuji Fukazawa
- b Department of Pediatrics , Nippon Medical School , Tokyo , Japan
| | - Makoto Watanabe
- b Department of Pediatrics , Nippon Medical School , Tokyo , Japan
| | - Koji Hashimoto
- b Department of Pediatrics , Nippon Medical School , Tokyo , Japan
| | - Nobuko Suzuki
- b Department of Pediatrics , Nippon Medical School , Tokyo , Japan
| | - Noriko Nagi-Miura
- c Laboratory for Immunopharmacology of Microbial Products , Tokyo University of Pharmacy and Life Sciences , Tokyo , Japan
| | - Naohito Ohno
- c Laboratory for Immunopharmacology of Microbial Products , Tokyo University of Pharmacy and Life Sciences , Tokyo , Japan
| | - Akira Shimizu
- d Department of Analytic Human Pathology , Nippon Medical School , Tokyo , Japan
| | - Yasuhiko Itoh
- b Department of Pediatrics , Nippon Medical School , Tokyo , Japan
| |
Collapse
|